Extending the time frame to 42 or 60 from 28 is lo

Extending the time frame to 42 or 60 from 28 is lowering the bar for approvals. Simple as that. FDA has been seeing most likely a significant amount of people pass away after day 28. Most likely to do with steroids or ventilators etc..we know placebo group would be worst off after day 28 vs someone who would have had received leronlimab. This update about mortality being looked at further from fda is a bonus gift. Frankly to me if our numbers are good at any interval of days it will be better than any other drug out there from big pharma or any company for that matter.,Leronlimab will likely be the new gold SOC.